
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD
GlobeNewsWire
Published: Jul 26, 2026, 09:33 PM GMT+9
Sentiment Analysis
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”), of the important August 31, 2026 lead plaintiff deadline.
If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet’s manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.
When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
Source: GlobeNewsWire
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.